GR1003164B - Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης. - Google Patents

Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.

Info

Publication number
GR1003164B
GR1003164B GR900100582A GR900100582A GR1003164B GR 1003164 B GR1003164 B GR 1003164B GR 900100582 A GR900100582 A GR 900100582A GR 900100582 A GR900100582 A GR 900100582A GR 1003164 B GR1003164 B GR 1003164B
Authority
GR
Greece
Prior art keywords
sepsis
ameliorating
symptoms
compositions
methods
Prior art date
Application number
GR900100582A
Other languages
English (en)
Other versions
GR900100582A (el
Inventor
C. John Mathison
Peter Tobias
Richard Ulevitch
D. Samuel Wright
Original Assignee
Scripps Clinic And Research Foundation
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic And Research Foundation, Rockefeller University filed Critical Scripps Clinic And Research Foundation
Publication of GR900100582A publication Critical patent/GR900100582A/el
Publication of GR1003164B publication Critical patent/GR1003164B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
GR900100582A 1989-08-01 1990-08-01 Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης. GR1003164B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01

Publications (2)

Publication Number Publication Date
GR900100582A GR900100582A (el) 1991-12-30
GR1003164B true GR1003164B (el) 1999-07-05

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100582A GR1003164B (el) 1989-08-01 1990-08-01 Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.

Country Status (14)

Country Link
US (4) US5730980A (el)
EP (1) EP0485430B1 (el)
JP (1) JP2744130B2 (el)
AT (1) ATE171042T1 (el)
AU (1) AU645515B2 (el)
CA (1) CA2022429C (el)
DE (1) DE69032662T2 (el)
DK (1) DK0485430T3 (el)
ES (1) ES2120948T3 (el)
FI (1) FI920450A0 (el)
GR (1) GR1003164B (el)
IE (1) IE902770A1 (el)
PT (1) PT94869B (el)
WO (1) WO1991001639A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2744130B2 (ja) * 1989-08-01 1998-04-28 スクリップス クリニック アンド リサーチ ファウンデーション 敗血症治療用組成物
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
CA2133758A1 (en) * 1992-04-06 1993-10-14 Sanna M. Goyert A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
EP0751962B1 (en) * 1993-05-28 2006-08-02 The Scripps Research Institute Methods for inhibiting cd14 mediated cell activation
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ATE308994T1 (de) 1994-09-16 2005-11-15 Scripps Research Inst Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
WO1996020957A1 (en) * 1994-12-30 1996-07-11 Amgen Inc. Anti-inflammatory cd14 polypeptides
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
NZ505070A (en) 1996-05-10 2005-01-28 Xoma Corp An in vitro method for inhibiting Neisseria meningitidis bacteria of serogroups A, B, C and W135 using BPI
EP0907372B1 (en) * 1996-05-23 2003-03-12 XOMA Technology Ltd. Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
KR100600518B1 (ko) * 1998-02-07 2006-07-13 브리티쉬 바이오테크 파마슈티칼스 리미티드 항균제
HUP0101987A3 (en) * 1998-05-27 2010-01-28 Gemma Biotechnology Ltd The induction of antibiotic peptides by lait (scd14) protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
EP1213586A4 (en) * 1999-09-17 2003-02-05 Mochida Pharm Co Ltd METHOD FOR FRACTIONAL MEASUREMENT OF SOLUBLE CD14 PROTEIN
JPWO2002042333A1 (ja) * 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
EP1348443A4 (en) * 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
WO2003105898A1 (en) * 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
AU2004241069B2 (en) 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
AU2006218876A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN101189334B (zh) 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CN110831975A (zh) * 2017-04-21 2020-02-21 因普利西特生物科学私人有限公司 用于治疗神经退行性疾病的cd14拮抗剂抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
JP2744130B2 (ja) * 1989-08-01 1998-04-28 スクリップス クリニック アンド リサーチ ファウンデーション 敗血症治療用組成物

Also Published As

Publication number Publication date
DE69032662D1 (de) 1998-10-22
PT94869B (pt) 1997-04-30
ATE171042T1 (de) 1998-10-15
FI920450A0 (fi) 1992-01-31
WO1991001639A1 (en) 1991-02-21
CA2022429C (en) 1998-12-01
US6045795A (en) 2000-04-04
CA2022429A1 (en) 1991-02-02
EP0485430B1 (en) 1998-09-16
DK0485430T3 (da) 1999-06-14
PT94869A (pt) 1991-04-18
ES2120948T3 (es) 1998-11-16
US6495332B2 (en) 2002-12-17
AU6146190A (en) 1991-03-11
DE69032662T2 (de) 1999-03-11
JPH05501399A (ja) 1993-03-18
JP2744130B2 (ja) 1998-04-28
US6297049B1 (en) 2001-10-02
EP0485430A4 (en) 1993-03-03
US5730980A (en) 1998-03-24
GR900100582A (el) 1991-12-30
IE902770A1 (en) 1991-02-27
AU645515B2 (en) 1994-01-20
US20020034509A1 (en) 2002-03-21
EP0485430A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
GR1003164B (el) Μεθοδοι και συνθεσεις για την βελτιωση των συμπτωματων της σηψης.
IL124536A (en) Pharmaceutical compositions containing a glycine uptake antagonist
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
CA2289717A1 (en) Novel therapy for constipation
GB2128088B (en) Oral mopidamol preparations
EG19304A (en) Method of treating pre-menstrual syndrome
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
HUT59833A (en) Process for producing pharmaceutical compositions containing calcitoninogene like peptides for treating erectional disfunctions
EP0792162A4 (en) USE OF ANTIBODIES TO PREVENT EFFECTS CAUSED BY GRAMPOSITIVE AND MYKO BACTERIA
HU911929D0 (en) Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
DE3478749D1 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
EP0736033A4 (en) NOVEL MIXTURES OF THERAPEUTIC CARBON HYDRATES TO RELIEVE PREMENSTRUAL SYNDROME
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
MY103872A (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function.
HUT61466A (en) Process for producing pharmaceutical compositions suitable for treating symptoms of detoxication cures
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
LT99101A (en) A medicament against infertility and for increasing frtility
PT80214A (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
ES481109A1 (es) Un metodo de preparacion de un extracto de stephania cepha- rantha.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
MA Right expired